- Home
- TMO vs AZN Comparison
TMO vs AZN Comparison
Compare TMO & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMO
- AZN
- Stock Information
- Founded
- TMO 1956
- AZN 1992
- Country
- TMO United States
- AZN United Kingdom
- Employees
- TMO N/A
- AZN N/A
- Industry
- TMO Industrial Machinery/Components
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- TMO Industrials
- AZN Health Care
- Exchange
- TMO Nasdaq
- AZN Nasdaq
- Market Cap
- TMO 203.5B
- AZN 228.9B
- IPO Year
- TMO N/A
- AZN 1993
- Fundamental
- Price
- TMO $395.16
- AZN $69.85
- Analyst Decision
- TMO Buy
- AZN Strong Buy
- Analyst Count
- TMO 17
- AZN 3
- Target Price
- TMO $597.24
- AZN $95.00
- AVG Volume (30 Days)
- TMO 2.6M
- AZN 4.0M
- Earning Date
- TMO 07-23-2025
- AZN 07-24-2025
- Dividend Yield
- TMO 0.44%
- AZN 2.18%
- EPS Growth
- TMO 9.37
- AZN 22.71
- EPS
- TMO 17.06
- AZN 4.97
- Revenue
- TMO $42,898,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- TMO $2.89
- AZN $9.56
- Revenue Next Year
- TMO $6.12
- AZN $6.09
- P/E Ratio
- TMO $23.02
- AZN $28.35
- Revenue Growth
- TMO 0.95
- AZN 15.48
- 52 Week Low
- TMO $385.46
- AZN $61.24
- 52 Week High
- TMO $627.88
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- TMO 39.10
- AZN 43.77
- Support Level
- TMO $385.46
- AZN $72.18
- Resistance Level
- TMO $424.51
- AZN $75.38
- Average True Range (ATR)
- TMO 9.45
- AZN 0.99
- MACD
- TMO -0.20
- AZN -0.34
- Stochastic Oscillator
- TMO 15.67
- AZN 1.65
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.